November 4, 2016

Nissan Chemical, - where unique & solution meet

Presentation for Investors 1H FY2016 (April 1 – September 30, 2016) Financial Results

Presented by Junichi Miyazaki, Director and Senior Executive Vice President

Translation of presentation materials for the investor meeting held in Tokyo on November 4, 2016



NISSAN CHEMICAL INDUSTRIES, LTD.


1H FY2016 PL

(¥billion)

	1H FY2015	1H FY2016	Change	Change (%)	1H FY2016 Outlook as of May 2016
Sales	83.7	Record 84.5	+0.8	+1.0%	86.0
Operating Profit	14.3	Record 14.7	+0.4	+3.3%	13.3
Non-Operating Income/Expenses	0.8	-0.5	-1.3	-160.4%	0.0
Ordinary Income	15.1	14.2	-0.9	-6.1%	13.3
Extraordinary Income/Loss	0.0	0.0	+0.0	-	0.0
Net Income (1)	11.1	10.6	-0.5	-4.9%	10.2
EBITDA (2)	18.7	18.8	+0.1	+0.5%	17.6
EPS (¥)	71.21	69.00	-2.21	-3.1%	66.56
Dividend (¥/share)	18	24	+6		24
Total amount of Dividend	2.8	3.7	+0.9		3.7
OP Margin	17.0%	17.4%	+0.4%		15.5%
FX Rate (¥/\$)	122	105			115
Naphtha (¥/KL) (3)	48,000	31,400			35,400
Comprehensive Income	9.6	7.4			

- (1) Net income = Profit Attributable to Owners of Parent
- (2) EBITDA = Operating Profit + Depreciation
- (3) Based on Trade Statistics of Japan Ministry of Finance (1H FY2016: Based on actual April-September data)

1H FY2016 Review



1H FY2016Non-Operating Income/Expenses, Extraordinary Income/Loss,
Comprehensive Income1H1HChange(¥billion)

prehensive Income	1H	1H	Change	(¥I
	FY2015	FY2016	Change	
Non-Operating Income	1.57	0.89	-0.68	
Interest income, dividend income	0.25	0.30	+0.05	
Share of profit of entities accounted for using equitymethod	0.45	0.15	-0.30	
Foreign exchange gains	0.13	0.00	-0.13	
Others	0.74	0.44	-0.30	
Non-Operating Expenses	0.71	1.41	+0.70	
Interest expense	0.11	0.09	-0.02	
Foreign exchange losses	0.00	0.63	+0.63	
Loss on disposal of fixed assets	0.13	0.26	+0.13	
Others	0.47	0.43	-0.04	
Extraordinary Income	-	-	-	
Extraordinary Loss	-	-	-	
Comprehensive Income	9.56	7.44	-2.12	
Net income	11.15	10.60	-0.55	
Non-controlling interests	0.10	0.07	-0.03	
Unrealized gains or losses on investment securities	-1.24	-2.32	-1.08	
Foreign currency translation adjustments	-0.41	-0.87	-0.46	
Remeasurements of defined benefit plans	-0.04	-0.04	+0.00	

1H FY2016 Cash Flow

(¥billion)

	1H	1H
	FY2015	FY2016
CF from operating activities	27.6	29.4
Profit before income tax	15.1	14.2
Depreciation & amortization	4.4	4.1
Тах	-4.0	-4.9
Working capital, others	12.1	16.0
CF from investing activities	-4.7	-4.5
Purchase of PPE	-4.3	-5.3
Others	-0.4	0.8
CF from financing activities	-27.3	-26.6
Dividends paid	-3.5	-4.0
Borrowings	-17.7	-17.5
Share repurchase	-6.0	-5.0
Others	-0.1	-0.1
Effect of FX rate changes on cash & cash equivalents	-0.2	-0.3
Change in cash & cash equivalents	-4.6	-2.0
Cash & cash equivalents at end of period	26.9	33.3

Balance Sheets as of September 30, 2016

(¥billion)

	2015/9	2016/3 (A)	2016/9 (В)	Change (B) - (A)		2015/
Current assets	115.9	142.2	120.4	-21.8	Liabilities	54
Cash	26.9	35.3	33.3	-2.0	Accounts payable	13
Accounts receivable	43.4	57.6	43.6	-14.0	Borrowings	17
Inventories	38.1	38.5	36.8	-1.7	Others	23
Others	7.5	10.8	6.7	-4.1	Net assets	150
Fixed assets	89.6	86.0	84.3	-1.7	Shareholders' equity	138
Total PPE	47.0	47.5	48.6	+1.1	Unrealized gains or losses on investment securities	9
Intangible assets	5.0	0.9	1.5	+0.6	Foreign currency translation adjustments	0
Investment securities	33.5	33.3	28.7	-4.6	Non-controlling interests	1
Others	4.1	4.3	5.5	+1.2	Remeasurements of defined benefit plans	0
Total assets	205.5	228.2	204.7	-23.5	Total liabilities & Net assets	205
	•				- Equity Potio	70.7

				• •
	2015/9	2016/3 (A)	2016/9 (B)	Change (B) - (A)
Liabilities	54.7	71.3	49.7	-21.6
Accounts payable	13.6	15.4	13.1	-2.3
Borrowings	17.4	33.1	15.5	-17.6
Others	23.7	22.8	21.1	-1.7
Net assets	150.8	156.9	155.0	-1.9
Shareholders' equity	138.8	144.2	145.6	+1.4
Unrealized gains or losses on investment securities	9.4	10.5	8.2	-2.3
Foreign currency translation adjustments	0.5	0.2	-0.7	-0.9
Non-controlling interests	1.5	1.5	1.5	+0.0
Remeasurements of defined benefit plans	0.6	0.5	0.4	-0.1
Total liabilities & Net assets	205.5	228.2	204.7	-23.5
• Equity Ratio • D/E Ratio (1) • Change in shareho	72.7% -6.9%	68.1% -1.6% ity +1.4		

Change in shareholders' equity +1.4

= Net Income 10.6 - Dividend and others 9.2

(1)D/E Ratio = (Borrowings - Cash) / Shareholders' equity

(Blank)

FY2016 Outlook

(¥billion)

	FY2	015 Ac	tual	_	FY2016 Outlook as of Nov. 2016			Change				FY2016 Outlook as of May 2016		
	1H	2H	Total	1H Actual	2H	Total	1H Actual	2H	Total	Total	1H	2H	Total	
Sales	83.7	93.2	176.9	84.5	96.0	Record 180.5	+0.8	+2.8	+3.6	+2%	86.0	101.5	187.5	
Operating Profit	14.3	14.3	28.6	14.7	15.2	Record 29.9	+0.4	+0.9	+1.3	+5%	13.:	16.4	29.7	
Non-Operating Income/Expenses	0.8	0.1	0.9	-0.5	0.3	-0.2	-1.3	+0.2	-1.1	-122%	0.0	0.7	0.7	
Ordinary Income	15.1	14.4	29.5	14.2	15.5	Record 29.7	-0.9	+1.1	+0.2	+1%	13.:	3 17.1	30.4	
Extraordinary Income/Loss (1)	0.0	-1.2	-1.2	0.0	0.0	0.0	+0.0	+1.2	+1.2	-	0.0	0.0	0.0	
Net Income (2)	11.1	11.3	22.4	10.6	11.9	Record 22.5	-0.5	+0.6	+0.1	+1%	10.2	2 12.8	23.0	
EBITDA (3)	18.7	19.6	38.3	18.8	20.8	39.6	+0.1	+1.2	+1.3	+3%	17.0	5 22.1	39.7	
EPS (¥/share) (4)	71.21	72.16	143.37	69.00	77.88	146.88	-2.21	+5.72	+3.51	+2%	66.5	6 83.80	150.36	
Dividend (¥/share)	18	26	44	24	26	50	+6	+0	+6		2	4 26	50	
Total amount of Dividend (4)	2.8	4.0	6.8	3.7	3.9	7.6	+0.9	-0.1	+0.8		3.7	3.9	7.6	
OP Margin	17.0%	15.4%	16.2%	17.4%	15.8%	16.6%	+0.4%	+0.4%	+0.4%		15.59	6 16.2%	15.8%	
ROE (4)	-	-	14.6%	-	-	14.2%			-0.4%				14.3%	
FX Rate (¥/\$)	122	118		105	105		•				11	5 115		
Naphtha (¥/kl)	48,000	37,700		31,400	34,400						35,4	0 35,40		
Comprehensive Income	9.6	11.9	21.5	7.4										

(1) FY2015 Actual: Gain on sales of investment securities+3.0, Impairment loss(TMAT*) -3.9,

Provision for loss on business of an affiliated company (Ammonia Terminal Company, Itd**) -0.3

- (2) Net income = Profit Attributable to Owners of Parent
- (3) EBITDA = Operating Profit + Depreciation
- (4) FY2016 Outlook including effects of FY2016 share repurchase program ended on August, 2016

TMAT* (consolidated subsidiary)

=Thin Materials AG(Germany) 100% subsidiary of Nissan Chem Temporary bonding materials for 3D packaging for semis Ammonia Terminal Company, Itd** (affiliated company)

=Joint venture company owned by Sumitomo Chem(40%), Showa Denko(30%) and Nissan Chem(30%)

2H FY2016 Outlook

<vs. 2h="" fy2015=""> <mark>(Sales</mark>)</vs.>	♦Up	¥2.8 billion (+3%)	(十) Performance Materials, Agrochemicals, Trading (土) Chemicals (一) Pharmaceuticals
(OP)	♦Up	¥0.9 billion (+6%)	(+) Agrochemicals, Trading (–) Chemicals, Performance Materials, Pharmaceuticals
(Non-Operating Income			
and Expenses)	♦Up	¥0.2 billion	
(Ordinary Income)	♦Up	¥1.1 billion (+8%)	
(Net Income)	♦Up	¥0.6 billion (+6%)	
(EPS)	♦Up	¥5.72 (+7.9%)	
<vs. 2h="" as<="" fy2016="" outlook="" td=""><td>s of May 2</td><td>016></td><td></td></vs.>	s of May 2	016>	
(Sales)	Down	¥5.5 billion	 (-) Chemicals, Performance Materials, Agrochemicals, Pharmaceuticals, Trading
(OP)	Down	¥1.2 billion	(+) Agrochemicals, Trading (-) Chemicals, Performance Materials, Pharmaceuticals
(Ordinary Income)	♦ Down	¥1.6 billion	
(Net Income)			
(EPS)	♦ Down	¥5.92	

<Shareholders Return>

(Dividend)

1H ¥24/share, 2H ¥26/share
 (1H up ¥6, 2H flat vs. FY2015)
 (1H, 2H flat vs. FY2016E as of May 2016)

Full Year FY2016 Outlook

<vs. fy2015=""></vs.>	(Sales)	♦Up	¥3.6 billion (+2%)	(+) Performance Materials, Agrochemicals, Trading (–) Chemicals, Pharmaceuticals
	(OP)	♦Up	¥1.3 billion (+5%)	 (+) Agrochemicals, Trading (-) Chemicals, Performance Materials, Pharmaceuticals
(Non-Operatin	g Income			
and E	xpenses)	Down	¥1.1 billion	
(Ordinar	y Income)	♦Up	¥0.2 billion (+1%)	
(Ne	et Income)	♦Up	¥0.1 billion (+1%)	
	(EPS)	♦Up	¥3.51 (+2%)	
	(ROE)	◆14.2%	(-0.4%)	
	(· · · ·	Net Income expected to renew the highest results
<vs. fy2016="" outl<="" td=""><td></td><td>-</td><td></td><td><i></i></td></vs.>		-		<i></i>
			¥7.0 billion	 (+) Agrochemicals, Pharmaceuticals (-) Chemicals, Performance Materials, Trading
	(OP)	♦Up	¥0.2 billion	 (+) Agrochemicals (±) Performance Materials, Pharmaceuticals, Trading (-) Chemicals
	-		¥0.7 billion	
(Ne	et Income)	•		
	(EPS)	♦Down	¥3.48	
	(ROE)	◆14.2%	(-0.1%)	
<shareholders r<="" td=""><td>leturn></td><td></td><td></td><td></td></shareholders>	leturn>			
((Dividend)	(1	/share, 2H ¥26/share H up ¥6, 2H flat vs. F H, 2H flat vs. FY2016	Y2015)
(Share Re	purchase)	♦¥5.0 bi	llion, 2 million share	s completed in August 2016 nares in May 2016, 1 million shares in August 2016)
(Total Sha				
Retu	rn Target)	• 70% (5	6% based on the ab	ove Share Repurchase and Dividend)

FY2016 Outlook Non-Operating Income/Expenses, Extraordinary Income/Loss

(¥billion)

FY2015 Actual	FY2016 Outlook as of Nov. 2016	Change		FY2016 Outlook as of May. 2016
2.48	1.97	-0.51		1.84
0.60	0.63	+0.03		0.59
0.86	0.60	-0.26		0.70
0.00	0.00	+0.00		0.00
1.02	0.74	-0.28		0.55
1.56	2.21	+0.65		1.18
0.19	0.16	-0.03		0.20
0.32	0.73	+0.41		0.64
0.17	0.63	+0.46		0.00
0.88	0.69	-0.19		0.34
3.08	0.00	-3.08		0.00
4.25	0.00	-4.25		0.00
	Actual 2.48 0.60 0.86 0.00 1.02 1.56 0.19 0.32 0.17 0.88 3.08	FY2015 Actual Outlook as of Nov. 2016 2.48 1.97 0.60 0.63 0.86 0.60 0.00 0.00 1.02 0.74 1.56 2.21 0.19 0.16 0.32 0.73 0.17 0.63 0.88 0.69	FY2015 ActualOutlook as of Nov. 2016Change2.481.97-0.510.600.63+0.030.860.60-0.260.000.00+0.001.020.74-0.281.562.21+0.650.190.16-0.030.320.73+0.410.170.63+0.460.880.69-0.19	FY2015 ActualOutlook as of Nov. 2016Change2.481.97-0.510.600.63+0.030.860.60-0.260.000.00+0.001.020.74-0.281.562.21+0.650.190.16-0.030.320.73+0.410.170.63+0.460.880.69-0.19

FY2016 Cash Flow Outlook

(¥billion)

	FY2015	FY2016 Outlook	FY2016 Outlook
	Actual	as of Nov. 2016	as of May 2016
CF from operating activities	30.0	31.4	30.9
Profit before income tax	28.4	29.7	30.3
Gain on sales of investment securities	-3.0	-0.2	0.0
Impairment loss	3.9	0.0	0.0
Provision for loss on business of associates	0.3	0.0	0.0
Depreciation & Amortization	9.7	9.7	10.0
Тах	-7.4	-8.9	-9.2
Working capital, others	-1.9	1.1	-0.2
CF from investing activities	-8.4	-16.6	-14.4
Purchase of PPE	-9.1	-17.6	-17.1
Purchase and sales of investment securities	1.9	2.7	2.7
Others	-1.2	-1.7	0.0
CF from financing activities	-17.3	-14.8	-14.7
Dividends paid	-6.3	-7.7	-7.7
Borrowings	-1.9	-2.0	-2.0
Share repurchase	-9.0	-5.0	-5.0
Others	-0.1	-0.1	0.0
Effect of FX rate changes on cash & cash equivalents	-0.3	0.0	0.0
Change in cash & cash equivalents	4.0	0.0	1.8
Cash & cash equivalents at end of period	35.3	35.3	37.1

(Blank)

FY2016 Sales Outlook by Segment(1)

(¥billion)

		FY2015 ActualFY2016 Outlook as of Nov. 2016			(Change			Change (%)			FY2016 Outlook as of May 2016				
		1H	2H	Total	1H Actual	2H	Total	1H Actual	2H	Total	1H Actual	2H	Total	1H	2H	Total
CI	nem	16.7	17.6	34.3	16.5	17.6	34.1	-0.2	+0.0	-0.2	-1%	-0%	-1%	17.5	17.9	35.4
	Fine	5.5	5.1	10.6	5.3	5.0	10.3	-0.2	-0.1	-0.3	-3%	-3%	-3%	5.7	5.2	10.9
	Basic	11.2	12.5	23.7	11.2	12.6	23.8	+0.0	+0.1	+0.1	-0%	+1%	+0%	11.8	12.7	24.5
	erfor- ance	26.0	25.8	51.8	25.5	27.0	52.5	-0.5	+1.2	+0.7	-2%	+5%	+1%	26.6	28.7	55.3
Ag	gro	21.1	26.4	47.5	24.0	28.2	52.2	+2.9	+1.8	+4.7	+13%	+7%	+10%	22.3	29.8	52.1
Ы	narma	3.7	5.0	8.7	3.7	3.9	7.6	+0.0	-1.1	-1.1	-1%	-21%	-12%	3.4	4.0	7.4
Tr	ading	27.5	28.1	55.6	27.6	30.6	58.2	+0.1	+2.5	+2.6	+0%	+9%	+5%	28.8	31.2	60.0
0	thers	8.9	12.0	20.9	8.6	14.8	23.4	-0.3	+2.8	+2.5	-3%	+23%	+12%	8.8	14.4	23.2
	djust- ent	-20.2	-21.7	-41.9	-21.4	-26.1	-47.5	-1.2	-4.4	-5.6	-	-	-	-21.4	-24.5	-45.9
Тс	otal	83.7	93.2	176.9	84.5	96.0	180.5	+0.8	+2.8	+3.6	+1%	+3%	+2%	86.0	101.5	187.5

(1) Including inter-segment sales/transfers


FY2016 OP Outlook by Segment

(¥billion)


	FY2	FY2015 Actual			FY2016 Outlook as of Nov. 2016			Change			Change (%)			FY2016 Outlook as of May 2016		
	1H	2H	Total	1H Actual	2H	Total	1H Actual	2H	Total	1H Actual	2H	Total	1H	2H	Total	
Chem	1.4	2.5	3.9	1.3	2.4	3.7	-0.1	-0.1	-0.2	-6%	-6%	-6%	1.6	3.3	4.9	
Perfor- mance	6.3	5.7	12.0	6.2	5.5	11.7	-0.1	-0.2	-0.3	-3%	-3%	-3%	5.8	5.9	11.7	
Agro	6.2	4.6	10.8	6.9	5.9	12.8	+0.7	+1.3	+2.0	+10%	+29%	+18%	5.8	5.5	11.3	
Pharma	0.6	1.4	2.0	0.6	0.8	1.4	+0.0	-0.6	-0.6	+0%	-44%	-30%	0.4	1.0	1.4	
Trading	0.9	0.9	1.8	0.8	1.1	1.9	-0.1	+0.2	+0.1	-2%	+11%	+5%	0.9	1.0	1.9	
Others	0.0	0.5	0.5	0.0	0.7	0.7	+0.0	+0.2	+0.2	-143%	+36%	+47%	0.0	0.8	0.8	
Adjust- ment	-1.1	-1.3	-2.4	-1.1	-1.2	-2.3	+0.0	+0.1	+0.1	-	-	-	-1.2	-1.1	-2.3	
Total	14.3	14.3	28.6	14.7	15.2	29.9	+0.4	+0.9	+1.3	+3%	+6%	+5%	13.3	16.4	29.7	

Chemicals – (A) Flow Chart of Selected Basic and Fine Chemicals Products


Core products of Basic Chemicals : Ammonia related products and sulfuric acid related products FY2015 ammonia domestic production capacity share 11%, high percentage of self-consumption of ammonia



Chemicals – (B) 1H FY2016 Sales Distribution




Chemicals – (C) Growing Products



⁽¹⁾ Marginal Profit : Sales – Variable Cost

Chemicals – (D-1) Production Capacity

Production Capacity (FY2012 Production Capacity = 100)



(1) Including subcontractors

Completed Cost Saving Investments at Toyama Ammonia Related Plants

Construction Cost: ¥0.5 billion Cost Savings: ¥0.2-0.3billion/year Contents: Utility and manpower savings

Ammonia Feedstock Change Project

See Page D-2

Chemicals – (D-2) Ammonia Feedstock Change Project

Project:

Change of feedstock for ammonia production at Toyama Plant from naphtha to natural gas

Purpose:


To pursue more stable profitability from ammonia and its derivative products by using natural gas

Construction Cost:
¥ 1.09 billion

Completion Period: Completed in August 2016 as scheduled

Extraordinary Loss:

Extraordinary loss of ¥ 704 million incurred in 3Q FY2014 (fiscal year ending in March 2015) as cost for dismantling the existing naphtha pipeline after completion of the project



Chemicals – (E) Fine Chemicals Subsegment

1H FY2016 Sales Review

<vs. 1H FY2015>

- ♦ TEPIC
- Environmental related products
- : Sales for general applications down due to strong yen, sales for electronic materials up
- : Domestic sales up, export sales down

<vs. 1H FY2016 Outlook as of May 2016> ♦ TEPIC

- : Both applications below target
- Environmental related products
- : Domestic sales above target, export sales below target

2H FY2016 Sales Outlook

<vs. 2H FY2015>

- ♦ TEPIC
- Environmental related products
- : Sales for general applications up, sales for electronic materials down
- : Domestic sales up, export sales flat

<vs. 2H FY2016 Outlook as of May 2016>

- ♦ TEPIC
- Environmental related products
- : Sales for general applications below target, sales for electronic materials in line with target
- : Domestic and export sales below target

					Sales	YOY C	hange			
	Main Products	FY2	015 Ac	tual)16 Out f May 2		FY2016 Outlook as of Nov. 2016		
		1H	2H	Total	1H	2H	Total	1H Actual	2H	Total
Total Subsegment		+4%	-3%	+1%	+4%	+3%	+3%	-3%	-3%	-3%
TEPIC	 Epoxy compound for : (A) electronic materials (solder resist, LED sealant), (B) general applications such as powder coating agent for paint World largest producer 	-8%	-17%	-12%	+9%	+9%	+9%	-9%	+2%	-4%
Env ironmental related products	HI-LITE : made from chlorinated isocyanuric acid, used for sterilizing, disinfectant for swimming pool as well as water purification tank	+18%	+9%	+14%	+0%	+0%	+4%	+2%	+5%	+3%

Two products account for 72% of total consolidated subsegment sales (FY2015)

Chemicals – (F) Basic Chemicals Subsegment

<u>1H FY2016 Sales Review</u> <vs. 1h="" fy2015=""></vs.>	
♦Melamine	: Domestic sales down, export sales up
◆Urea/AdBlue	: Urea flat, AdBlue up
High purity sulfuric acid	: Flat
<vs. 1h="" as="" fy2016="" o<="" outlook="" td=""><td>f May 2016></td></vs.>	f May 2016>
♦Melamine	: Domestic sales below target, export sales above target
◆Urea/AdBlue	: Both urea and AdBlue below target
High purity sulfuric acid	: Below target due to lower consumption by domestic semis customers
2H FY2016 Sales Outlook	
<vs. 2h="" fy2015=""></vs.>	
♦Melamine	: Both domestic and export sales down
◆Urea/AdBlue	: Urea down, AdBlue up
♦ High purity sulfuric acid	: Up
we 2H EV2016 Outlook as o	f May 2016

<vs. 2H FY2016 Outlook as of May 2016>

♦Melamine	: Domestic sales below target, export sales above target
◆Urea/AdBlue	: Both urea and AdBlue in line with target
High purity sulfuric acid	: Below target

					Sales	YOY C	hange			
	Main Products	FY2	015 Ac	tual)16 Out of May 2		FY2016 Outlook as of Nov.2016		
		1H	2H	Total	1H	2H	Total	1H Actual	2H	Total
Total Subsegment		-2%	+2%	+0%	+5%	+2%	+3%	-0%	+1%	+0%
Melamine	Mainly used as adhesive agent for particle board, medium density fiberboard, plywood	+11%	+15%	+13%	-1%	-11%	-6%	+1%	-7%	-3%
Urea/AdBlue	 Urea: mainly used for urea formaldehyde resin, adhesive agent AdBlue: solution of urea in demineralised water for diesel trucks to reduce Nox 		+13%	+10%	+11%	+2%	+7%	+2%	+1%	+1%
High purity sulfuric acid	 ♦ Used to clean semiconductors ♦ Largest in domestic market 	-12%	-3%	-8%	+5%	+8%	+7%	-1%	+4%	+2%

Three products account for 39% of total consolidated subsegment sales(FY2015)

Chemicals – (G) Profit Overview

(¥billion)

														•	,
	FY2015 Actual (A)				16 Out of May 2		FY201 as c	6 Outlo	• • •		Change B) — (A			ange(% 3)—(A)	-
	1H	2H	Total	1H	2H	Total	1H Actual	2H	Total	1H Actual	2H	Total	1H Actual	2H	Total
Sales	16.7	17.6	34.3	17.5	17.9	35.4	16.5	17.6	34.1	-0.2	+0.0	-0.2	-1%	-0%	-1%
Fine	5.5	5.1	10.6	5.7	5.3	10.9	5.3	5.0	10.3	-0.2	-0.1	-0.3	-3%	-3%	-3%
Basic	11.2	12.5	23.7	11.8	12.6	24.5	11.2	12.6	23.8	+0.0	+0.1	+0.1	-0%	+1%	+0%
OP	1.4	2.5	3.9	1.6	3.3	4.9	1.3	2.4	3.7	-0.1	-0.1	-0.2	-6%	-6%	-6%

1H FY2016 Review

<vs. 1H FY2015>

(Fine Chemicals)

- Environmental related products sales up, TEPIC sales down
- Inventory adjustment cost up
- Sales down, OP down

(Basic Chemicals)

- Sales of melamine and urea including AdBlue up, high purity sulfuric acid down
- Fuel cost down
- Sales flat, OP up

(Total Segment)

Sales down ¥0.2billion, OP down ¥0.1billion

<vs. 1H FY2016 Outlook as of May 2016>

(Fine Chemicals)

- Environmental related products sales above target
- ◆ TEPIC sales below target
- Strong yen
- Sales below target, OP below target

(Basic Chemicals)

- Sales of melamine above target, sales of urea including AdBlue and high purity sulfuric acid below target
- Strong yen
- Fuel cost lower than expectations
- Sales below target, OP below target

(Total Segment)

Sales down ¥1.0billion, OP down ¥0.3billion

2H FY2016 Outlook <vs. 2H FY2015>

(Fine Chemicals)

- Environmental related products sales up, TEPIC sales up
- Fuel cost down
- Sales down, OP up

(Basic Chemicals)

- Sales of melamine down
- Sales of urea including AdBlue and high purity sulfuric acid up
- Sales up, OP down

(Total Segment)

Sales flat, OP down ¥0.1billion

<vs. 2H FY2016 Outlook as of May 2016>

(Fine Chemicals)

- ◆ Sales of environmental related products and TEPIC below target
- Strong yen
- Inventory adjustment cost up
- ◆ Sales below target, OP below target

(Basic Chemicals)

- Sales of melamine above target
- Sales of urea including AdBlue in line with target
- Sales of high purity sulfuric below target
- Strong yen
- Inventory adjustment cost up
- Sales below target, OP below target

(Total Segment)

Sales down ¥0.3billion, OP down ¥0.9billion

(Blank)

Performance Materials – (A) Display Materials

1H FY2016 Sales Review

- - IPS/FFS up, TN and VA down
 - Photo-alignment IPS SUNEVER sales increasing substantially

<vs. 1H FY2016 Outlook as of May 2016>

- SUNEVER above target
- IPS/FFS above target, TN and VA below target

2H FY2016 Sales Outlook

- - IPS/FFS and VA up, TN down
 - Photo-alignment IPS SUNEVER sales increasing substantially

<vs. 2H FY2016 Outlook as of May 2016>

- SUNEVER below target
- TN, VA and IPS/FFS below target

	Sales YOY Change												
Main Products	FY2	2015 Act	ual		016 Out of May 2		FY2016 Outlook as of Nov. 2016						
	1H	2H	Total	1H	2H	Total	1H Actual	2H	Total				
Total SUNEVER	+18%	+9%	+13%	+3%	+7%	+5%	+4%	+2%	+3%				
Other Display Materials (1)	+1%	+15%	+7%	+80%	+189%	+136%	-3%	+35%	+16%				
Total Display Materials	+18%	+9%	+13%	+4%	+9%	+7%	+4%	+3%	+3%				

(1) NHC(protective coating for touch panels), 3D TV materials, Elsource (hole injection layer materials for OLED),etc

• Purchased patents and expertise of OLED hole injection and hole transport materials from Solvay (September 2016)

Performance Materials – (B) Semis Materials

1H FY2016 Sales Review

<vs. 1H FY2015>

Total Semis Materials sales down -6%

<vs. 1H FY2016 Outlook as of May 2016>

Total Semis Materials sales below target

2H FY2016 Sales Outlook

<vs. 2H FY2015>

Total Semis Materials sales up +11%

<vs. 2H FY2016 Outlook as of May 2016>

Total Semis Materials sales below target

KrF, ArF and other semis materials down

KrF above target, ArF and other semis materials below target

KrF, ArF and other semis materials up

KrF, ArF and other semis materials below target

					Sales	YOY Ch	ange				
	Main Products	FY2	2015 Act	ual		016 Outl of May 20		FY2016 Outlook as of Nov . 2016			
		1H	2H	Total	1H	2H	Total	1H Actual	2H	Total	
	KrF	+1%	-7%	-3%	-9%	+4%	-3%	-8%	+3%	-3%	
	ArF	+3%	+5%	+4%	+7%	+15%	+11%	-1%	+6%	+2%	
Bc	ttom anti-reflective coating (ARC®) Total	+2%	-0%	+1%	+0%	+11%	+6%	-3%	+5%	+1%	
Ot	her Semis Materials (1)	-23%	-22%	-23%	+6%	+58%	+31%	-15%	+36%	+10%	
То	tal Semis Materials	-4%	-5%	-5%	+2%	+20%	+11%	-6%	+11%	+3%	

(1) Multi layer process materials (OptiStack®), microlens materials, etc

• Semiconductor capex plan to capture long-term future business:

Main capex (approval basis): FY2014 Analyzing and evaluation R&D equipment (¥1.1 billion)

FY2015 Product development facilities(¥2.8 billion),


Analyzing and evaluation R&D equipment (¥0.8 billion),

Production capacity expansion (¥0.8 billion), NCK (¥0.7 billion)

FY2016 NCK production capacity expansion (¥3.2 billion),

Analyzing and evaluation R&D equipment (¥1.0 billion)

Performance Materials – (C-1) Inorganic Materials



Performance Materials - (C-2) SNOWTEX, Organo sol

1H FY2016 Sales Review

<vs. 1H FY2015>

- **SNOWTEX** : Down (sales for polishing materials down, sales for non-polishing materials up)
- ♦ Organo sol : Down

<vs. 1H FY2016 Outlook as of May 2016>

- **SNOWTEX** : Above target (sales for polishing materials and non-polishing materials above target)
- Organo sol : Above target

2H FY2016 Sales Outlook

<vs. 2H FY2015>

- **SNOWTEX** : Up (sales for polishing materials flat, sales for non-polishing materials up)
- ♦ Organo sol : Flat

<vs. 2H FY2016 Outlook as of May 2016>

- **SNOWTEX** : Above target (sales for polishing materials and non-polishing materials above target)
- Organo sol : Above target

				S	Sales Y	OY Cha	ange (1)		
	Main Products	FY2	015 Ac	tual)16 Out f May 2		FY2016 Outlook as of Nov. 2016		
		1H	2H	Total	1H	2H	Total	1H Actual	2H	Total
SNOWTEX	 Mainly Used for : (A) polishing materials (silicon wafer, aluminum and glass hard disk), (B) non-polishing materials 	+4%	+1%	+2%	-5%	-3%	-4%	-4%	+2%	-1%
Organo sol	Used for : hard coating materials, electronic information materials	+18%	-4%	+6%	-11%	-8%	-10%	-7%	-1%	-4%

(1) Non-consolidated basis

Performance Materials – (D) Profit Overview

(¥billion)

	FY2015 Actual (A)			FY2015 Actual (A)FY2016 Outlook as of May 2016				FY2016 Outlook(B) as of Nov. 2016				Change B) — (A		Change(%) (B)-(A)		
	1H	2H	Total	1H	2H	Total	1H Actual	2H	Total	1H Actual	2H	Total	1H Actual	2H	Total	
Sales	26.0	25.8	51.8	26.6	28.7	55.3	25.5	27.0	52.5	-0.5	+1.2	+0.7	-2%	+5%	+1%	
OP	6.3	5.7	12.0	5.8	5.9	11.7	6.2	5.5	11.7	-0.1	-0.2	-0.3	-3%	-3%	-3%	

1H FY2016 Review <vs. 1H FY2015>

- SUNEVER sales up (IPS/FFS up, TN and VA down)
- Total Semis Materials sales down (KrF, ArF and other semis materials down)
- Inorganic Materials sales down (SNOWTEX and Organo sol down)
- Fixed cost up ¥0.4billion
- Sales down ¥0.5billion, OP down ¥0.1billion

<vs. 1H FY2016 Outlook as of May 2016>

- SUNEVER sales above target (IPS/FFS above target, TN and VA below target)
- Total Semis Materials sales below target (KrF above target, ArF and other semis materials below target)
- Inorganic Materials sales below target (SNOWTEX and Organo sol above target)
- Fixed cost down ¥0.4billion
- Sales down ¥1.1billion, OP up ¥0.4billion

2H FY2016 Outlook <vs. 2H FY2015>

- SUNEVER sales up (IPS/FFS and VA up, TN down)
- Total Semis Materials sales up (KrF, ArF and other semis materials up)
- Inorganic Materials sales up (SNOWTEX up, Organo sol down)
- Fixed cost up ¥1.0billion
- Sales up ¥1.2billion, OP down ¥0.2billion

<vs. 2H FY2016 Outlook as of May 2016>

- SUNEVER sales below target (TN, VA and IPS/FFS below target)
- Total Semis Materials sales below target (KrF, ArF and other semis materials below target)
- Inorganic Materials sales below target (SNOWTEX and Organo sol above target)
- Fixed cost down ¥0.1billion
- Sales down ¥1.7billion, OP down ¥0.4billion

(Blank)

Agrochemicals – (A) Sales YOY Change (Before Discount)

			Non-consolidated Sales YOY Change			
Main Products (in order of FY2015 sales amount)		FY2015 /FY2014	FY2016E /FY2015 as of May 2016	FY2016E /FY2015 as of Nov. 2016		
ROUNDUP	herbicide					
ALTAIR (NC-620)	herbicide					
TARGA	herbicide					
PERMIT	herbicide				YOY Change	
SIRIUS	herbicide				+15%~ +10~+15%	1111 111
PULSOR (THIFLUZAMIDE)	fungicide		////		+5~+10% +0~+5%	11 1
LEIMAY/OR ACLE	fungicide				-0~-5%	N.
STAR MITE	miticide				-5~-10% -10~-15%	¥¥ ¥¥¥
SANMITE	insecticide				-15%~	****

Agrochemicals – (B) Overview

Transforming from a stable profit sector into a high growth sector driven by ALTAIR (new paddy rice herbicide), ROUNDUP and FLURALANER

Strengthening product portfolio by: in-house developed products, acquired products, licensed-in products

(launch) (products) FY2002 **ROUNDUP** (herbicide, acquired domestic business from Monsanto) FY2008 **LEIMAY** (fungicide. in-house) **STARMITE** (miticide, in-house) FY2009 **PULSOR (THIFLUZAMIDE)** (fungicide, acquired from Dow) **PREVATHON** (insecticide, licensed from DuPont) FY2010 **AVH** (herbicide, licensed from ZEN-NOH, Bayer and Hokko) **ROUNDUP AL** for general household shower-type herbicide market, growing sharply FY2011-12 ALTAIR (paddy rice herbicide, in-house) launched in Korea in FY2011 and in Japan in FY2012 Shipment of fluralaner to MSD started in July as scheduled **FY2013 FY2014** BRAVECTO launched in several countries in EU in April and in the USA in June by MSD EXIREL/PRYROSSO (CYAZYPYR) launched (insecticide, licensed from DuPont) FY2015 **BRAVECTO** launched in Japan in July by Intervet K.K TREFANOCIDE (herbicide, acquired by Gowan from Dow, exclusive sales right in Japan transferred to NCI) FY2017-18 ISOCLAST (SULFOXAFLOR) (insecticide, licensed from Dow) **ISOPYRAZAM** (fungicide, licensed from Syngenta) **Insecticide** (in-house) FY2019 FY2022 **General fungicide (in-house)** MSD: MSD Animal Health, the global animal health business unit of Merck

MSD: MSD Animal Health, the global animal health business unit of Intervet K.K: a Japanese subsidiary of MSD

- Full reconstruction of Biological Research Laboratories for Agro and Pharma segments FY2010-2017 Total capex ¥6.4 billion (FY2015-2017 last phase ¥1.3 billion)
- Acquired 3% share of IHARABRÁS (leading agro company in Brazil) in September 2011
- Established subsidiaries in China (April 2014) and Brazil (August 2016) for sales support and new product development
- Export sales account for 31% of FY2015 non-consolidated segment sales (Asia:30%, Europe/Africa:52%, North/Central/South America:18%) *Including Fluralaner

Agrochemicals – (C) Fluralaner

♦Fluralaner

Invented by NCI and supplied to MSD as the active pharmaceutical ingredient of BRAVECTO

BRAVECTO

*Developed by MSD Animal Health

*Veterinary medical product (chewable tablets) providing unique immediate and persistent tick and flea killing activity for dogs for 12 weeks, longer than currently available once-monthly commercialized products

*Launched by MSD in Germany, Spain, Italy, France, the Netherlands and the United Kingdom in April 2014, and in the USA in June 2014 (at present, launched in about 70 countries)

*Launched by Intervet K.K. in Japan in July 2015

*BRAVECTO Spot-On Solution for dogs and cats approved in EU in May and in USA in July

*BRAVECTO Spot-On Solution for cats launched in EU in July 2016 and USA in October 2016

Agrochemicals – (D) Non-consolidated Segment Sales (before discount)

				Non-c	onsolida	ted Sale	s YOY Ch	nange				
	FY2013 Actual	FY2014 Actual	FY2015 Actual				2016 Outlo of May 20		FY2016 Outlook as of Nov . 2016			
	Total	Total	1H	2H	Total	1H	2H	Total	1H Actual	2H	Total	
ROUNDUP	-0%	+17%	+2%	-3%	-0%	+6%	+5%	+5%	+20%	+7%	+13%	
(ROUNDUP AL(1))	(+66%)	(+59%)	(+27%)	(+62%)	(+36%)	(+11%)	(-31%)	(-1%)	(+26%)	(+4%)	(+20%)	
Others(2)	+14%	+13%	+18%	-2%	+5%	+7%	+12%	+10%	+12%	+6%	+8%	
Total Segment	+11%	+14%	+14%	-2%	+4%	+7%	+11%	+9%	+14%	+6%	+9%	

(1) ROUNDUP for general household, launched in FY2010, accounting for 15% of FY2015 ROUNDUP sales (2) Including Fluralaner

	Distributio Non-consoli			NCI's Strategy		Distribution of the Total Domestic Market
	FY2014	FY2015		Strengthening product lines	1	Oct 2014-Sept 2015
Fungicide +Insecticide	1%	1%		· LEIMAY, STARMITE, PULSOR		11%
Insecticide	14%	13%		• New in-house developed products		29%
Fungicide	12%	12%		New licensed-in products		22%
Herbicide	71%	71%		 New acquisitions 		35%
Plant growth regulator	2%	2%				2%
Others	1%	1%		Maintaining strong market positions		1%
Total (3)	100%	100%		- ALTAIR, ROUNDUP AL		100%

(3) Excluding Fluralaner

Agrochemicals – (E) Profit Overview

	-														<i>y</i>
	FY2015 Actual (A)			FY2016 Outlook as of May 2016			FY2016 Outlook(B) as of Nov. 2016			Change (B) – (A)			Change(%) (B)(A)		
	1H	2H	Total	1H	2H	Total	1H Actual	2H	Total	1H Actual	2H	Total	1H Actual	2H	Total
Sales	21.1	26.4	47.5	22.3	29.8	52.1	24.0	28.2	52.2	+2.9	+1.8	+4.7	+13%	+7%	+10%
OP	6.2	4.6	10.8	5.8	5.5	11.3	6.9	5.9	12.8	+0.7	+1.3	+2.0	+10%	+29%	+18%

1H FY 2016 Review <vs. 1H FY2015>

- Sales up : Fluralaner, ROUNDUP (ML, AL), ALTAIR, TARGA(export), TREFANOCIDE
- Sales down : PERMIT (export), PULSOR (export), STARMITE, SIRIUS
- Fixed cost up
- Inventory adjustment cost up ¥0.4billion
- Sales up ¥2.9billion, OP up ¥0.7billion

<vs. 1H FY2016 Outlook as of May 2016>

- Sales above target : Fluralaner, ROUNDUP (ML, AL), ALTAIR
 Sales below target : PERMIT (export), PULSOR (export),
- Sales below target : PERMIT (export), PULSOR (exp
- Fixed cost down
- Inventory adjustment cost up ¥0.2billion
- Sales up ¥1.7billion, OP up ¥1.1billion

2H FY 2016 Outlook <vs. 2H FY2015>

(¥hillion)

- Sales up : Fluralaner, ROUNDUP (ML, AL), ALTAIR, TREFANOCIDE, LEIMAY
- Sales down : TARGA (export), PERMIT (export), SIRIUS
- Fixed cost down
- Inventory adjustment cost up ¥0.5billion
- Sales up ¥1.8billion, OP up ¥1.3billion


<vs. 2H FY2016 Outlook as of May 2016>

- Sales above target : ALTAIR, ROUNDUP (AL), STARMITE (export)
 Sales below target : TARGA (export), Fluralaner, SIRIUS, PULSOR (export), ISOCLAST
- Fixed cost down
- Inventory adjustment cost up ¥0.2billion
- Sales down ¥1.6billion, OP up ¥0.4billion

(Blank)

Pharmaceuticals – (A) NCI Business Model

Unique ethical pharma business model without sales force



API*: Active Pharmaceutical Ingredient

Pharmaceuticals – (B) LIVALO (Anti-Cholesterol Drug)

	FY2013 Actual	FY2014 Actual	FY2015 Actual	FY2016 Outlook as of May 2016	FY2016 Outlook as of Nov. 2016
Domestic End Market Sales (NHI drug price basis, ¥billion)	52.6	34.5	29.7	-	-
Domestic End Market Share (1)	21%	16%	15%	-	-
Our Domestic and Export API Sales (¥billion)	10.2	6.9	5.8	4.7	5.1
Our Domestic and Export API Sales YOY Change	-2%	-32%	-15%	-19%	-13%
(Our Domestic API Sales YOY Change)	(-2%)	(-46%)	(-27%)	(-37%)	(-41%)

(1) Excluding generic

- August 2013, domestic compound patent expired
- April 2014, filed complaints against certain companies in USA which had submitted Abbreviated New Drug Application(ANDA) with FDA
- Domestic market share 15% in FY2015
- ♦ FY2016 NHI drug price cut about -7~-9%

Full reconstruction of Biological Research Laboratories (FY2010-2017)

FY2015 Domestic Market Share(1) Crestor 53% Lipitor 18% LIVALO 15% Mevalotin 8%

Pharmaceuticals – (C) LIVALO World Wide Strategy

Region	Country	Launch	Business Partner
	Japan	Sep 2003	Kowa
	Korea	Jul 2005	JW Pharmaceutical
Asia	Thailand	Jan 2008	Biopharm Chemicals
ASId	China	Jul 2009	Kowa (Shanghai) Pharma
	Indonesia	May 2012	Tanabe Indonesia
	Taiwan	Jun 2012	Taiwan Tanabe
North America	USA	Jun 2010	Kowa (KPA)
Latin America	Mexico, Brazil, Colombia, Venezuela	Feb 2012-	Eli Lilly
Europe	Spain, Portugal, Ukraine, Greece,Switzerland	May 2011-	Recordati
Middle and Near East	Lebanon, Jordan, UAE, Kuwait, Saudi Arabia	Mar 2011-	Algorithm SAL

Selling in total 21 countries

Pharmaceuticals – (D) Pipeline

Product	Mechanism of action	Expected indications	Development partners					
NIP-022	Thrombopoietin (TPO) receptor activation	• Thrombocytopenia	 Terminated the license agreement with Ono in April 2014 Entered into the license agreement with Yakult in October 2015 Started Phase I clinical trials in Japan in July 2016 					
NT-702	 Phosphodiesterase (PDE)3 inhibition 	 Intermittent claudication Asthma 	 Terminated the license agreement with Taisho Under consideration regarding seeking new partners 					
NTC-801	 Acetylcholine-activated K⁺ channel current (IKACh) inhibition 	• Arrhythmia (Atrial fibrillation)	 Terminated the license agreement with Teijin and BMS in September 2015 Under consideration regarding seeking new partners 					

Strategic Research Collaboration with Shionogi

- Started in January 2016 for novel antifungal drug candidates

Novel drug discovery research

To create innovative medicines by using the strategic chemical library, the precise organic synthesis technology and the state-of-the-art evaluation technology;

- In-house research : Focusing on cardiovascular disease and neurological disease as core therapeutic areas.
- Collaborative research : Utilizing open innovation effectively (*e.g.* Shionogi)

Pharmaceuticals – (E) Custom Chemicals

 Custom manufacturing and process researching services for pharmaceutical ingredients and intermediates from pre-clinical to commercial production stages

- October 2013, Custom Chemicals shifted from Chemicals Segment to Pharma Segment to seek synergy of the two divisions (organic synthesis technology, R&D/manufacturing/quality control systems)
- Focusing on obtaining new contracts including high activity and high-valued added GE API products (Prostaglandin and vitamin D3, etc.)

1H FY2016 Sales Review

<vs. 1H FY2015>

- Up due to volume increase in existing products
- <vs. 1H FY2016 Outlook as of May 2016>
- Above target (existing products sales above target, high value-added generic API product sales above target)

2H FY2016 Sales Outlook

<vs. 2H FY2015>

- Up (existing products sales up, a new contracts expected)
- <vs. 2H FY2016 Outlook as of May 2016>
 - Above target (some shipments of the high value-added generic API product shifted to FY2017, a new contract expected)

	Sales YOY Change												
FY2	2015 Act	ual		016 Outl of May 20	FY2016 Outlook as of Nov. 2016								
1H	2H	Total	1H	2H	Total	1H Actual	2H	Total					
-6%	+68%	+27%	-5%	+2%	-1%	+10%	+3%	+6%					

Pharmaceuticals – (F) Profit Overview

(¥billion)

	FY2015 Actual (A)			FY2016 Outlook as of May 2016			FY2016 Outlook(B) as of Nov. 2016				Change B) — (A		Change(%) (B)-(A)		
	1H	2H	Total	1H	2H	Total	1H Actual	2H	Total	1H Actual	2H	Total	1H Actual	2H	Total
Sales	3.7	5.0	8.7	3.4	4.0	7.4	3.7	3.9	7.6	+0.0	-1.1	-1.1	-1%	-21%	-12%
OP	0.6	1.4	2.0	0.4	1.0	1.4	0.6	0.8	1.4	+0.0	-0.6	-0.6	0%	-44%	-30%

1H FY 2016 Review <vs. 1H FY2015>

- LIVALO sales down (domestic down due to GE, export up)
- Custom Chemicals sales up
- Fixed cost down
- Sales flat, OP flat

<vs. 1H FY2016 Outlook as of May 2016>

- LIVALO sales above target (domestic sales below target due to shipments shifted to 2H, export above target)
- Custom Chemicals sales above target
- Sales up ¥0.3billion, OP up ¥0.2billion

2H FY 2016 Outlook <vs. 2H FY2015>

- LIVALO sales down (domestic down due to GE, export up)
- Custom Chemicals sales up
- Absence of up-front payment on pipeline products
- Fixed cost down
- Sales down ¥1.1billion, OP down ¥0.6billion

<vs. 2H FY2016 Outlook as of May 2016>

- LIVALO sales above target (domestic sales above target due to shipments shifted from 1H, export above target)
- Custom Chemicals sales above target
- Absence of up-front payment on pipeline products
- Fixed cost up
- Sales down ¥0.1billion, OP down ¥0.2billion

Capex/Depreciation/R&D by Segment

	apex	(1)												
		`		Depreciation (2)					R&D expenses					
2013	2014	2015	2016E	2012	2013	2014	2015	2016E	2012	2013	2014	2015	2016E	% of Sales
1.2	1.4	2.3	2.1	1.6	1.4	1.4	1.4	1.6	0.4	0.4	0.5	0.5	0.5	1.4%
4.3	5.2	5.4	9.4	3.7	3.2	3.6	5.2	5.2	6.5	6.3	6.7	7.4	8.3	15.0%
1.3	1.8	1.3	2.6	1.9	2.0	1.8	1.4	1.4	3.0	3.5	3.5	3.9	3.6	6.9%
0.6	0.4	0.4	0.8	1.5	1.2	0.9	0.8	0.7	2.6	2.9	2.7	2.4	2.2	29.7%
0.0	0.0	0.0	0.0	0.1	0.1	0.1	0.1	0.1	0.0	0.0	0.0	0.0	0.0	-
1.4	0.1	0.8	0.5	0.7	0.6	0.7	0.8	0.7	1.2	1.1	1.6	1.6	1.5	-
8.8	9.8	10.2	15.4	9.5	8.5	8.5	9.7	9.7	13.7	14.2	15.0	15.8	16.1	
	4.3 1.3 0.6 0.0 1.4	1.21.44.35.21.31.80.60.40.00.01.40.1	1.21.42.34.35.25.41.31.81.30.60.40.40.00.00.01.40.10.8	1.21.42.32.14.35.25.49.41.31.81.32.60.60.40.40.80.00.00.00.01.40.10.80.5	1.21.42.32.11.64.35.25.49.43.71.31.81.32.61.90.60.40.40.81.50.00.00.00.00.11.40.10.80.50.7	1.21.42.32.11.61.44.35.25.49.43.73.21.31.81.32.61.92.00.60.40.40.81.51.20.00.00.00.00.10.11.40.10.80.50.70.6	1.21.42.32.11.61.41.44.35.25.49.43.73.23.61.31.81.32.61.92.01.80.60.40.40.81.51.20.90.00.00.00.00.10.10.11.40.10.80.50.70.60.7	1.2 1.4 2.3 2.1 1.6 1.4 1.4 1.4 4.3 5.2 5.4 9.4 3.7 3.2 3.6 5.2 1.3 1.8 1.3 2.6 1.9 2.0 1.8 1.4 0.6 0.4 0.4 0.8 1.5 1.2 0.9 0.8 0.0 0.0 0.0 0.1 0.1 0.1 0.1 1.4 0.1 0.8 0.5 0.7 0.6 0.7 0.8	1.21.42.32.11.61.41.41.41.64.35.25.49.43.73.23.65.25.21.31.81.32.61.92.01.81.41.40.60.40.40.81.51.20.90.80.70.00.00.00.10.10.10.10.10.11.40.10.80.50.70.60.70.80.7	1.21.42.32.11.61.41.41.41.60.44.35.25.49.43.73.23.65.25.26.51.31.81.32.61.92.01.81.41.43.00.60.40.40.81.51.20.90.80.72.60.00.00.00.10.10.10.10.10.10.01.40.10.80.50.70.60.70.80.71.2	1.2 1.4 2.3 2.1 1.6 1.4 1.4 1.4 1.6 0.4 0.4 4.3 5.2 5.4 9.4 3.7 3.2 3.6 5.2 5.2 6.5 6.3 1.3 1.8 1.3 2.6 1.9 2.0 1.8 1.4 1.4 3.0 3.5 0.6 0.4 0.4 0.8 1.5 1.2 0.9 0.8 0.7 2.6 2.9 0.0 0.0 0.0 0.1 0.1 0.1 0.1 0.0 0.0 1.4 0.1 0.8 0.5 0.7 0.6 0.7 0.8 0.7 1.2 1.1	1.2 1.4 2.3 2.1 1.6 1.4 1.4 1.4 1.6 0.4 0.4 0.5 4.3 5.2 5.4 9.4 3.7 3.2 3.6 5.2 5.2 6.5 6.3 6.7 1.3 1.8 1.3 2.6 1.9 2.0 1.8 1.4 1.4 3.0 3.5 3.5 0.6 0.4 0.4 0.8 1.5 1.2 0.9 0.8 0.7 2.6 2.9 2.7 0.0 0.0 0.0 0.1 0.1 0.1 0.1 0.0	1.2 1.4 2.3 2.1 1.6 1.4 1.4 1.4 1.6 0.4 0.4 0.5 0.5 4.3 5.2 5.4 9.4 3.7 3.2 3.6 5.2 5.2 6.5 6.3 6.7 7.4 1.3 1.8 1.3 2.6 1.9 2.0 1.8 1.4 1.4 3.0 3.5 3.5 3.9 0.6 0.4 0.4 0.8 1.5 1.2 0.9 0.8 0.7 2.6 2.9 2.7 2.4 0.0 0.0 0.0 0.1 0.1 0.1 0.1 0.0 0	1.2 1.4 2.3 2.1 1.6 1.4 1.4 1.6 0.4 0.4 0.5 0.5 4.3 5.2 5.4 9.4 3.7 3.2 3.6 5.2 5.2 6.5 6.3 6.7 7.4 8.3 1.3 1.8 1.3 2.6 1.9 2.0 1.8 1.4 1.4 3.0 3.5 3.5 3.9 3.6 0.6 0.4 0.4 0.8 1.5 1.2 0.9 0.8 0.7 2.6 2.9 2.7 2.4 2.2 0.0 0.0 0.0 0.1 0.1 0.1 0.1 0.0

(1) Capex

Actual - Acceptance basis

Outlook - Production commencement basis

(2) Depreciation Method

SUNEVER, ARC®, OptiStack®

- 4 year declining balance method

(50.0% of initial capex amount in the 1st year) Other products - 8 year declining balance method

(25.0% of initial capex amount in the 1st year)

R&D expenses/Sales 8.9% 8.7% 8.7% 8.9% 8.9%

R&D Personnel (Sept. 2016) –A	430
Total Professionals (Sept. 2016) –B	1,090
A/B	39%

※Parent company only

%Round number

Main Capex Items (Approval Basis)

(¥billion)

FY2013 Actual		FY2014 Actual		FY2015 Actual	FY2016 Outlook as of Nov. 2016				
Chemical Research Lab. (Instruments)	0.8	Reconstruction of Biological Research Lab. The fifth stage (Facilities)	1.3	Semis (Product development facilities)	2.8	NCK Semis (Production capacity expansion)	3.2		
Electronic Materials Lab. (Instruments)	0.8	Semis (Analyzing and evaluation R&D equipment)	1.1	Material Research Lab. (Instruments)	2.2	Chemicals (Product development plant)	1.2		
Reconstruction of Biological Research Lab. The fourth stage (Facilities)	05	Ammonia Feedstock Change Project	1.1	Agro (Formulation facilities)	1.2	Material Research Lab. (Instruments)	1.1		
		Electronic Materials Lab. (Instruments)	0.9	SUNEVER (Raw materials products)	1.0	Semis (Analyzing and evaluation R&D equipment)	1.0		
		Quality improvement of Inorganic Materials products	0.7	Semis (Analyzing and evaluation R&D equipment)	0.8	Chemical Research Lab. (Instruments)	0.6		
		Chemical Research Lab. (Instruments)	0.6	Semis (Production capacity expansion)	0.8	Biological Research Lab. (Instruments)	0.3		
		NCK R&D Center (Instruments)	0.3	NCK Semis (Production capacity expansion)	0.7	NCK SUNEVER (Production capacity expansion)	0.3		
				Custom Chemicals (Production capacity expansion)	0.4	NCK R&D Center (Instruments)	0.2		
				TEPIC (Production capacity expansion)	0.3		·		
				Biological Research Lab. (Instruments)	0.2				
				NCK R&D Center (Instruments)	0.2		46		
						-	40		

Financial Strategy

(A) Share Repurchase to Enhance ROE

- Started share repurchase in 2006
- Repurchased ¥50.5 billion, 33.7 million shares (18.0% of shares issued) in total from FY2006 to FY2016
- Cancelled all repurchased shares

Shareholders Return FY2006 - 2016

Fiscal year	2006	2007	2008	2009	2010	2011	2012	2013	2014	2015	2016	Total
Shares purchased (thousand shares)	3,500	3,399	7,355	0	2,167	0	6,372	3,263	2,764	3,333	1,584	33,737
Purchase costs (¥billion)	4.7	5.0	8.0	0.0	2.8	0.0	5.0	5.0	6.0	9.0	5.0	50.5
Shares cancelled (thousand shares)	3,000	3,635	7,000	0	3,000	0	6,000	4,000	3,000	2,000	2,000	33,635
Shares issued at FY end (million shares)	185	181	174	174	171	171	165	161	158	156	154	
Treasury share at FY end (thousand shares)	1,367	1,233	1,660	1,709	885	886	1,258	522	287	1,621		
Dividend (¥billion)	3.7	3.6	3.8	4.2	4.1	4.1	4.3	4.9	5.7	6.8		
Dividend (¥/Share)	20	20	22	24	24	24	26	30	36	44		
Total payout ratio (dividend + share repurchase) (%)	60	56	118	32	53	37	67	59	64	71		

Repurchase plan announced on May 12, 2016

- Total number of shares repurchased :1.6 million shares
- Total amount

:¥ 5.0 billion

- Period of repurchase :From May 13, 2016 to August 2, 2016
- Cancellation of shares
- Total number of shares cancelled :1.0 million shares (May 10, 2016)
- Total number of shares cancelled :1.0 million shares (August 31, 2016)

(B) Cash Management Policy

Aiming to control cash balance around the level of

- = Minimum required level
 - + 1/3 of annual scheduled long-term borrowings repayment
 - + 1/3 of short-term borrowings outstanding + Contingent risk reserves

(Blank)

Mid-Term Business Plan Vista 2015 Stage II (FY2013-2015) FY2015 Financial Targets (Mid-Term Plan vs. Actual)(A)

1. PL	Mid-term Plar	Actu			V	/ariance					
(¥billion)	FY2015 (A)		FY2015 (B)				(B)-(A)				
Sales	18	176.9				-3.1					
Operating Profit	2	26.0			28.6	+2.6					
Ordinary Income	2	6.5	Achieved		29.5		+3.0				
Net Income	13	8.5	Achieved		22.4		+3.9				
EPS(¥)	113	.00	Achieved	14	43.37		+30.37				
FX Rate (¥/\$)		85	1H		122	2H	118				
Naphtha (¥/kl)	61,0	00	1H	48	8,000	2H	37,700				
2 Compart(4)	Mid-ter	m F	Plan			Act	tual		Variance		
2. Segment (1)	Sales (2)		ОР		Sal	es	OP		Sales		
(¥billion)	2015 (C)	2	015 (D)		2015	(E)	2015 (F)		(E) - (C)	(F)	
Chem	41.5		4.9			36.6	4.5		-4.9		
Performance M.	53.8		11.3			51.8	12.0		-2.0		
Agro	40.8		7.6			47.5	10.8		+6.7		
Pharma	7.9		3.5			6.4	1.4		-1.5		
Trading,Others,Adjustment	36.0		-1.3			34.6	34.6 -0.1		-1.4		
Total	180.0		26.0			176.9	28.6		-3.1		

(1) Former segmentation (2) Including inter-segment sales/transfers

OP

(F) - (D)

-0.4

+0.7

+3.2

-2.1

+1.2

+2.6

Mid-Term Business Plan Vista 2015 Stage II (FY2013-2015) FY2015 Sales Variance by Segment (Mid-Term Plan vs. Actual)(B)

	Sales Variance 2. (E) - (C)	FY2015 Actual > FY2015 Mid-term Plan	FY2015 Actual < FY2015 Mid-term Plan
Chem	-4.9	Melamine(domestic, export) TEPIC(general), Custom Chemicals	Ammonia, High purity sulfuric acid, TEPIC(electronic, liquid), Urea/AdBlue, Fertilizer, Environmental related products
Performance M.	-2.0	IPS/FFS, Photo-alignment IPS, ARC®(Bottom anti-reflective coating)	TN, VA, Other display materials, OptiStack® (Multi layer process materials), SNOWTEX(polishing, non-polishing), Organo sol, New products
Agro	+6.7	Fluralaner, ROUNDUP, ALTAIR, Export	LEIMAY, SIRIUS
Pharma	-1.5	LIVALO(export)	LIVALO(domestic) Up-front payment
Total	-3.1		

Mid-Term Business Plan Vista 2015 Stage II (FY2013-2015) FY2015 Financial Indicators (Mid-Term Plan vs. Actual)(C)

Highest importance on ROE as well as OP margin
 ROE : FY2015 Target 13.4% vs FY2015 Actual 14.6%

achieved

OP margin : FY2015 Target 14.4% vs FY2015 Actual 16.2% achieved

Dividend payout ratio above 30% vs FY2015 Actual 30.7%
 In addition, continue to repurchase shares timely

achieved

R&D expenses/sales :

FY2015 Target 9.6% vs FY2015 Actual 8.9%

(Blank)

Mid-Term Business Plan Vista 2021 (FY2016-2021) Financial Indicators (A)

2015	2016	2018	2021
176.9	187.5	217.0	250.0
28.6	29.7	35.0	40.0
29.5	30.4	35.6	40.8
22.4	23.0	27.1	31.0
16.2%	15.8%	16.1%	16.0%
14.6%	14.3%	above 14%	above 14%
30.7%	33.3%	40%	40%
70.8%	maintain 70%	maintain 70%	maintain 70%
	176.9 28.6 29.5 22.4 16.2% 14.6% 30.7%	176.9187.528.629.729.530.422.423.016.2%15.8%14.6%14.3%30.7%33.3%	176.9187.5217.028.629.735.029.530.435.622.423.027.116.2%15.8%16.1%14.6%14.3%above 14%30.7%33.3%40%

FX Rate (¥/\$)	1H	122	2H	118	FY2016 onv	ward 115		
Naphtha (¥/KL) (4)	1H 48	,000,	2H 37,	,700	1H 35,400	2H 35,400	FY2017 onward	51,100

(¥billion)

(¥hillion)

2 Segmentu		Sal	es			Operatin	ng Profit	
2. Segment(1)	2015	2016	2018	2021	2015	2016	2018	2021
Chem	34.3	35.4	38.0	40.5	3.9	4.9	4.0	4.5
Performance M.	51.8	55.3	68.0	82.9	12.0	11.7	15.4	18.4
Agro	47.5	52.1	58.6	67.0	10.8	11.3	12.9	16.7
Pharma	8.7	7.4	8.1	8.3	2.0	1.4	2.0	2.4
Trading,Others,Adjustment	34.6	37.3	44.3	51.3	-0.1	0.4	0.7	-2.0
Total	176.9	187.5	217.0	250.0	28.6	29.7	35.0	40.0


(1) Including inter-segment sales/transfers

Mid-Term Business Plan Vista 2021 (FY2016-2021) Financial Indicators (B)

OP Margin : Maintain above 15% (FY2015 Actual 16.2%)

- ROE : Maintain above 14% (FY2015 Actual 14.6%)
- Dividend Payout Ratio : Gradually increase to 40% in FY2018 (FY2015 Actual 30.7%)
- Total Payout Ratio : Maintain 70% (FY2015 Actual 70.8%) <u>New indicator</u>
- R&D expenses/sales : above 8% (FY2015 Actual 8.9%)

Long-term Financial Performance Trend



Long Term Financial Performance Trend

(¥billion)

	2003	2004	2005	2006	2007	2008	2009	2010	2011	2012	2013	2014	2015	2016E
Sales	155.9	161.4	169.1	174.4	169.2	160.2	149.0	154.2	148.6	153.8	163.7	171.2	176.9	180.5
Operating Profit	15.7	17.3	21.7	20.8	24.8	17.4	19.2	19.8	15.5	19.5	22.2	25.3	28.6	29.9
Ordinary Income	14.6	17.4	21.3	21.2	24.4	16.9	19.2	19.4	15.9	20.5	23.7	26.4	29.5	29.7
Net Income	8.7	11.3	13.7	14.0	15.5	10.1	12.8	13.0	11.0	13.9	16.7	18.2	22.4	22.5
EBITDA	26.1	26.9	31.6	30.5	34.5	27.6	30.1	30.2	25.9	29.0	30.8	33.8	38.3	39.6
OP Margin	10.0%	10.7%	12.8%	12.0%	14.6%	10.9%	12.8%	12.9%	10.4%	12.7%	13.6%	14.8%	16.2%	16.6%
ROE	13.4%	15.2%	16.1%	14.7%	15.6%	10.3%	12.6%	11.9%	9.5%	11.4%	12.7%	12.7%	14.6%	14.2%
EPS(¥/share)	46.21	59.77	72.73	75.43	85.15	57.26	74.00	75.94	64.52	83.74	102.11	113.99	143.37	146.88
Dividend(¥/share)	11	11	15	20	20	22	24	24	24	26	30	36	44	50
Dividend Payout Ratio	23.8%	18.4%	20.6%	26.5%	23.5%	38.4%	32.4%	31.6%	37.2%	31.0%	29.4%	31.6%	30.7%	34.0%
Share Repurchase	-	-	-	4.7	5.0	8.0	-	2.8	-	5.0	5.0	6.0	9.0	5.0
Total Assets	172.6	169.4	183.2	177.3	172.7	172.3	181.4	183.4	190.1	199.2	208.0	223.9	228.2	-
Net Assets	69.2	78.5	92.0	98.1	100.1	95.7	106.5	112.4	119.6	126.7	137.8	151.3	156.9	-
Cash	5.9	4.3	8.5	11.0	7.6	9.7	14.8	21.1	27.9	31.9	30.8	31.3	35.3	-
Liabilities with Interest	57.4	44.6	41.5	32.4	34.4	45.5	42.1	39.9	38.9	38.1	36.1	35.1	33.1	-
D/E Ratio	78.0%	53.7%	38.5%	23.2%	27.2%	37.1%	26.0%	16.9%	9.3%	5.0%	4.1%	2.7%	-1.6%	-
Equity Ratio	40.1%	46.4%	50.2%	55.3%	58.0%	55.5%	58.7%	60.7%	62.4%	63.0%	65.7%	66.9%	68.1%	-
Сарех	6.6	6.6	9.2	12.1	10.9	13.9	10.1	9.6	8.3	8.1	8.8	9.8	10.2	15.4
Depreciation	10.4	9.6	9.9	9.7	9.7	10.2	11.0	10.4	10.5	9.5	8.5	8.5	9.7	9.7
R&D Expenses	8.7	8.6	9.2	9.9	12.5	13.7	13.1	12.6	13.6	13.7	14.2	15.0	15.8	16.1
R&D Expenses/Sales	5.6%	5.3%	5.4%	5.7%	7.4%	8.6%	8.8%	8.2%	9.2%	8.9%	8.7%	8.7%	8.9%	8.9%

FY2011-2Q FY2013 Quarterly Sales by Segment₍₁₎ (Former Segmentation)

(¥billion)

												<u> </u>	
			FY2	2011 Actu	ual			FY2	2012 Acti	ual		FY2013	Actual
		1Q	2Q	3Q	4Q	Total	1Q	2Q	3Q	4Q	Total	1Q	2Q
C	hem	9.4	9.2	9.0	9.3	36.9	9.1	8.8	8.9	9.8	36.6	9.5	9.1
	Fine	3.0	2.9	2.4	2.6	10.9	2.9	2.7	2.4	3.2	11.2	2.9	3.1
	Basic	6.4	6.3	6.6	6.7	26.0	6.2	6.1	6.5	6.6	25.4	6.6	6.0
	erformance laterials	8.7	8.3	8.6	8.4	34.0	9.5	9.3	9.5	9.1	37.4	10.3	10.3
F	gro	7.1	5.4	3.7	17.6	33.8	8.3	5.1	4.6	17.4	35.4	9.9	6.1
F	harma	2.9	2.3	2.4	2.4	10.0	3.5	1.8	3.1	2.2	10.6	2.9	2.8
Т	rading	11.6	10.9	10.8	11.5	44.8	11.9	10.8	12.5	11.4	46.6	12.7	11.8
C	others	4.6	4.7	4.3	6.4	20.0	3.9	6.3	4.6	6.4	21.2	4.6	5.1
A	djustment	-7.7	-7.6	-7.3	-8.3	-30.9	-7.8	-9.4	-8.6	-8.2	-34.0	-9.7	-9.0
٦	otal	36.6	33.2	31.5	47.3	148.6	38.4	32.7	34.6	48.1	153.8	40.2	36.2

(1) Including inter-segment sales/transfers

FY2011-2Q FY2013 Quarterly OP by Segment (Former Segmentation)

(¥billion)

		FY2	2011 Actu	ual			FY2	2012 Act	ual		FY2013	Actual
	1Q	2Q	3Q	4Q	Total	1Q	2Q	3Q	4Q	Total	1Q	2Q
Chem	1.0	-0.2	0.6	0.2	1.6	0.8	0.0	0.4	0.7	1.9	0.8	0.0
Performance Materials	1.7	0.9	1.1	1.1	4.8	2.1	2.0	1.6	1.5	7.2	2.1	2.3
Agro	1.2	-0.4	-1.5	5.1	4.4	1.6	-0.3	-1.1	4.8	5.0	2.3	0.1
Pharma	1.4	1.2	1.0	1.0	4.6	1.9	0.7	1.6	1.0	5.2	1.6	1.5
Trading	0.4	0.3	0.3	0.3	1.3	0.4	0.3	0.4	0.3	1.4	0.4	0.3
Others	0.0	0.0	-0.1	0.4	0.3	-0.1	0.2	0.1	0.5	0.7	0.1	0.1
Adjustment	-0.5	-0.4	-0.4	-0.2	-1.5	-0.4	-0.6	-0.5	-0.4	-1.9	-0.6	-0.4
Total	5.2	1.4	1.0	7.9	15.5	6.3	2.3	2.5	8.4	19.5	6.7	3.9
OP Margin	14.3%	4.0%	3.4%	16.6%	10.4%	16.5%	6.8%	7.5%	17.4%	12.7%	16.7%	10.6%

FY2013-2Q FY2016 Quarterly Sales by Segment (1) (New Segmentation)

																	(¥	billion)
			FY	2013 Act	ual			FY	2014 Acti	ual			FY2	2015 Act	ual		FY2016	Actual
		1Q	2Q	3Q	4Q	Total	1Q	2Q	3Q	4Q	Total	1Q	2Q	3Q	4Q	Total	1Q	2Q
c	hem	9.3	8.6	8.8	8.8	35.5	8.5	8.2	9.1	8.5	34.3	8.7	8.0	9.0	8.6	34.3	8.5	8.0
	Fine	2.7	2.6	2.3	2.3	9.9	2.7	2.6	2.8	2.5	10.6	3.0	2.5	2.5	2.6	10.6	2.8	2.5
	Basic	6.6	6.0	6.5	6.5	25.6	5.8	5.6	6.3	6.0	23.7	5.7	5.5	6.5	6.0	23.7	5.7	5.5
	erformance laterials	10.3	10.3	11.1	11.1	42.8	11.8	12.4	13.0	12.2	49.4	13.0	13.0	13.6	12.2	51.8	12.6	12.9
A	gro	9.9	6.1	5.5	17.6	39.1	12.3	6.2	5.7	21.5	45.7	13.6	7.5	5.0	21.4	47.5	14.5	9.5
Р	harma	3.1	3.3	3.0	2.2	11.6	2.5	2.5	2.1	1.7	8.8	2.1	1.6	3.5	1.5	8.7	2.2	1.5
т	rading	12.7	11.8	12.8	13.4	50.7	14.1	13.2	14.1	13.0	54.4	14.7	12.8	14.9	13.2	55.6	14.4	13.2
С	others	4.6	5.1	4.9	6.8	21.4	3.8	4.7	4.6	7.8	20.9	4.1	4.8	4.7	7.3	20.9	4.0	4.6
A	djustment	-9.7	-9.0	-8.9	-9.8	-37.4	-10.5	-9.8	-10.7	-11.3	-42.3	-11.0	-9.2	-11.0	-10.7	-41.9	-11.1	-10.3
Т	otal	40.2	36.2	37.2	50.1	163.7	42.5	37.4	37.9	53.4	171.2	45.2	38.5	39.7	53.5	176.9	45.1	39.4
_																		

(1) Including inter-segment sales/transfers

(Vhillion)

FY2013-2Q FY2016 Quarterly OP by Segment (New Segmentation)

																(¥	(billion)
		FY	2013 Act	ual			FY2	2014 Actı	ual			FY2	2015 Act	ual		FY2016	Actual
	1Q	2Q	3Q	4Q	Total	1Q	2Q	3Q	4Q	Total	1Q	2Q	3Q	4Q	Total	1Q	2Q
Chem	1.0	-0.2	0.6	0.5	1.9	1.0	-0.6	0.6	0.9	1.9	1.5	-0.1	1.2	1.3	3.9	1.5	-0.2
Performance Materials	2.1	2.3	2.3	2.1	8.8	3.3	3.4	3.2	2.1	12.0	3.4	2.9	3.6	2.1	12.0	3.0	3.2
Agro	2.3	0.1	-0.8	4.6	6.2	4.0	0.0	-0.5	5.7	9.2	4.4	1.8	-1.3	5.9	10.8	4.5	2.4
Pharma	1.4	1.7	1.4	0.4	4.9	0.8	0.8	0.4	0.3	2.3	0.4	0.2	1.6	-0.2	2.0	0.6	0.0
Trading	0.4	0.3	0.4	0.4	1.5	0.5	0.4	0.5	0.3	1.7	0.5	0.4	0.5	0.4	1.8	0.4	0.4
Others	0.1	0.1	0.1	0.5	0.8	-0.1	0.0	0.1	0.6	0.6	0.0	0.0	0.0	0.5	0.5	0.0	0.0
Adjustment	-0.6	-0.4	-0.5	-0.4	-1.9	-0.6	-0.4	-0.7	-0.7	-2.4	-0.8	-0.3	-0.7	-0.6	-2.4	-0.5	-0.6
Total	6.7	3.9	3.5	8.1	22.2	8.9	3.6	3.6	9.2	25.3	9.4	4.9	4.9	9.4	28.6	9.5	5.2
OP Margin	16.7%	10.6%	9.3%	16.4%	13.6%	21.0%	9.6%	9.6%	17.2%	14.8%	20.9%	12.6%	12.5%	17.6%	15.8%	21.1%	13.3%

1H FY2016 Sales by Segment (1)

(¥billion)

								(
	11	H FY201	5		′2016 O u		11	H FY201	6
		Actual		aso	of May 2	016		Actual	
	1Q	2Q	Total	1Q	2Q	Total	1Q	2Q	Total
Chem	8.7	8.0	16.7	8.9	8.6	17.5	8.5	8.0	16.5
Fine	3.0	2.5	5.5	3.0	2.7	5.7	2.8	2.5	5.3
Basic	5.7	5.5	11.2	5.9	5.9	11.8	5.7	5.5	11.2
Performance Materials	13.0	13.0	26.0	13.1	13.5	26.6	12.6	12.9	25.5
Agro	13.6	7.5	21.1	12.2	10.1	22.3	14.5	9.5	24.0
Pharma	2.1	1.6	3.7	1.6	1.8	3.4	2.2	1.5	3.7
Trading	14.7	12.8	27.5	14.2	14.6	28.8	14.4	13.2	27.6
Others	4.1	4.8	8.9	4.1	4.7	8.8	4.0	4.6	8.6
Adjustment	-11.0	-9.2	-20.2	-10.7	-10.7	-21.4	-11.1	-10.3	-21.4
Total	45.2	38.5	83.7	43.4	42.6	86.0	45.1	39.4	84.5

(1) Including inter-segment sales/transfers

1H FY2016 OP by Segment

(¥billion)

		l FY201 Actual			/2016 Ou of May 2		11	H FY201 Actual	_
	1Q	2Q	Total	1Q	2Q	Total	1Q	2Q	Total
Chem	1.5	-0.1	1.4	1.5	0.1	1.6	1.5	-0.2	1.3
Performance Materials	3.4	2.9	6.3	2.8	3.0	5.8	3.0	3.2	6.2
Agro	4.4	1.8	6.2	3.0	2.8	5.8	4.5	2.4	6.9
Pharma	0.4	0.2	0.6	0.1	0.3	0.4	0.6	0.0	0.6
Trading	0.5	0.4	0.9	0.4	0.5	0.9	0.4	0.4	0.8
Others	0.0	0.0	0.0	-0.1	0.1	0.0	0.0	0.0	0.0
Adjustment	-0.8	-0.3	-1.1	-0.6	-0.6	-1.2	-0.5	-0.6	-1.1
Total	9.4	4.9	14.3	7.1	6.2	13.3	9.5	5.2	14.7

Sales and Operating Profit by Segment

(¥billion)

		FY2	010	FY2	011	FY2	012	FY2	013	FY2	014	FY2	015	FY20	16E							
	Chem	38.1	24.7%	36.9	24.8%	34.5	22.4%	35.5	21.7%	34.3	20.0%	34.3	19.4%	34.1	18.9%							
	Perf	38.0	24.6%	34.0	22.9%	37.4	24.3%	42.8	26.1%	49.4	28.9%	51.8	29.3%	52.5	29.1%							
S	Agro	34.4	22.3%	33.8	22.7%	35.4	23.0%	39.1	23.9%	45.7	26.7%	47.5	26.9%	52.2	28.9%							
ales	Pharma	9.6	6.2%	10.0	6.7%	12.7	8.3%	11.6	7.1%	8.8	5.1%	8.7	4.9%	7.6	4.2%							
	Trading	44.1	28.6%	44.8	30.1%	46.6	30.3%	50.7	31.0%	54.4	31.8%	55.6	31.4%	58.2	32.2%							
Æ	Others	27.0	17.5%	20.0	13.5%	21.2	13.8%	21.4	13.1%	20.9	12.2%	20.9	11.8%	23.4	13.0%							
	Adj	-37.0	-24.0%	-30.9	-20.8%	-34.0	-22.1%	-37.4	-22.8%	-42.3	-24.7%	-41.9	-23.7%	-47.5	-26.3%							
	Total	154.2	100%	148.6	100%	153.8	100%	163.7	100%	171.2	100%	176.9	100%	180.5	100%		FY2	012	FY2	014	FY2	045
																	F12	013	F I Z	014	F 12	015
	Chem	2.4	12.1%	1.6	10.3%	1.9	9.7%	1.9	8.6%	1.9	7.5%	3.9	13.6%	3.7	12.4%	S	25.8	12.4%	25.2	11.3%	26.6	11.7%
	Perf	7.9	39.9%	4.8	31.0%	7.2	36.9%	8.8	39.6%	12.0	47.4%	12.0	42.0%	11.7	39.1%	ıbe	38.0	18.3%	43.9	19.6%	40.9	17.9%
	Agro	4.8	24.2%	4.4	28.4%	5.0	25.6%	6.2	27.9%	9.2	36.4%	10.8	37.8%	12.8	42.8%	egment	48.6	23.4%	53.6	23.9%	52.9	23.2%
P	Pharma	4.4	22.2%	4.6	29.7%	5.2	26.7%	4.9	22.1%	2.3	9.1%	2.0	7.0%	1.4	4.7%	nt	12.7	6.1%	11.4	5.1%	11.1	4.9%
(B)	Trading	1.4	7.1%	1.3	8.4%	1.4	7.2%	1.5	6.8%	1.7	6.7%	1.8	6.3%	1.9	6.4%	As	18.1	8.7%	18.5	8.3%	19.5	8.5%
	Others	1.0	5.1%	0.3	1.9%	0.7	3.6%	0.8	3.6%	0.6	2.4%	0.5	1.7%	0.7	2.3%	Assets	9.1	4.4%	9.9	4.4%	10.1	4.4%
	Adj	-2.1	-10.6%	-1.5	-9.7%	-1.9	-9.7%	-1.9	-8.6%	-2.4	-9.5%	-2.4	-8.4%	-2.3	-7.7%		55.7	26.8%	61.4	27.4%	67.1	29.4%
	Total	19.8	1 00 %	15.5	100%	19.5	100%	22.2	100%	25.3	100%	28.6	1 00 %	29.9	100%	D)	208.0	1 00 %	223.9	100%	228.2	100%
	Chem		6.3%		4.3%		5.5%		5.4%		5.5%		11.4%		10.9%			7.4%		7.5%		14.7%
(c)	<mark>O</mark> Perf		20.8%		14.1%		19.3%		20.6%		24.3%		23.2%		22.3%	(23.2%		27.3%		29.3%
	A gro		14.0%		13.0%		14.1%		15.9%		20.1%		22.7%		24.5%	(E) =		12.8%		17.2%		20.4%
(B	Pharma		45.8%		46.0%		40.9%		42.2%		26.1%		23.0%		18.4%	ROA = (B)		38.9%		20.2%		18.0%
(B)/(A)	Trading		3.2%		2.9%		3.0%		3.0%		3.1%		3.2%		3.3%	0A (B)/(D)		8.3%		9.2%		9.2%
	Others		3.7%		1.5%		3.3%		3.7%		2.9%		2.4%		3.0%	3		8.3%		6.1%		5.0%
	Total		<mark>12.9%</mark>		<mark>10.4%</mark>		<mark>12.7%</mark>		<mark>13.6%</mark>		<mark>14.8%</mark>		<mark>16.2%</mark>		<mark>16.6%</mark>			1 0.7%		11.3%		12.5%

FY2010-2011 : Former Segmentation, FY2012-2016E : New Segmentation

New Segmentation (From October 1, 2013)

Former Segmentation

Segment		Main Products
Chem	Fine Chemicals	TEPIC Melamine cyanurate HI-LITE Custom Chemicals
	Basic Chemicals	Melamine Urea, AdBlue Ammonia, Sulfuric acid, Nitric acid High purity chemicals

Performance	SUNEVER, NHC,
Materials	ARC® (Bottom anti-reflective coating)
	OptiStack® (Multi layer process materials)
	Micro lens
	SNOWTEX, Organo silica sol
	Alumina sol, SUNCOLLOID
	CELNAX

Agro	Agro	Herbicides
		Insecticides
		Fungicide
	Active substa	nce of Veterinary medical product

Pharma LIVALO

Trading	Nissei Corporation	
Others	Nissan Butsuryu, Nissan Green & Landscape,	
	Nissan Engineering, Fertilizer	

Adjustment		R&D expenses of Advanced Materials & Planning Dept.
		included

New Segmentation Main Products Seament Chem TEPIC Fine Chemicals **Melamine cyanurate HI-LITE** Basic Melamine Chemicals Urea. AdBlue Ammonia, Sulfuric acid, Nitric acid High purity chemicals Performance SUNEVER, NHC, **Materials** ARC® (Bottom anti-reflective coating) **OptiStack® (Multi layer process materials)** Micro lens SNOWTEX, Organo silica sol Alumina sol. SUNCOLLOID CELNAX Herbicides Agro Agro Insecticides Fungicide Active substance of Veterinary medical product Pharma LIVALO **Custom Chemicals** Trading **Nissei Corporation** Others Nissan Butsuryu, Nissan Green & Landscape, Nissan Engineering, Fertilizer

Adjustment R&D expenses of Advanced Materials & Planning Dept. included

Main Products by Segment (New Segmentation)

Segment	Products	Main Applications
Chem	♦ Fine Chemicals	
	TEPIC	epoxy compound for LED sealants, solder resist, painting
	Melamine cyanurate	flame retardant
Ļ	Environmental product	HI-LITE (chlorinated isocyanuric acid for sterilizing)
	Basic Chemicals	
	Melamine	adhesive agent for plywood
	AdBlue	solution of urea in demineralised water for diesel trucks to reduce NOx
	Ammonia, Sulfuric acid, Nitric acid	
	High purity chemicals	agents used for cleaning semiconductors
	Electronic Materials SUNEVER	LOD -limment appting
Materials	SUNEVER ARC®	LCD alignment coating bottom anti-reflective coating for semiconductors
		multi layer process material for semiconductors (Si-HM/SOC)
	OptiStack®	*ARC® and OptiStack® are registered trade mark of Brewer Science, Inc.
	NHC	protective coating for touch panel
	OPTIFOCUS	microlens material for image sensor application
	ELSOURCE	hole injection layer materials for OLED
F	Inorganic Materials	
	SNOWTEX	water dispersed colloidal silica sol for polishing silicon wafers, special steel sheets, NOx
		reduction catalyst, electronic printing materials
	Organo silica sol	film coating, antistatic interference shielding, electronic printing materials
	Alumina sol	automotive catalyst, electronic printing materials
	SUNCOLLOID	high refractive sol for lens
	CELNAX	antistatic sol for film
Agro	◆ Herbicide	
~ I	TARGA	soybean, rapeseed, sugarbeet
	PERMIT	corn, sugarcane, rice
	SIRIUS, ALTAIR	paddyrice
	ROUNDUP	non-selective herbicide for orchard, noncrop land
	◆Insecticide	
	STARMITE, SANMITE, MITOKOHNE	fruits, tea, vegetables
	◆Fungicide	
	LEIMAY/ORACLE	vegetables, potato, fruits
	PULSOR, IKARUGA, GREATAM	
	(THIFLUZAMIDE)	potato, grape, turf
	Animal health products	
	Fluralaner (BRAVECTO)	active substance of BRAVECTO (veterinary medical product for dogs)
Pharma	LIVALO	Anti-cholesterol drug
	Custom Chemicals	custom manufacturing and process services for pharmaceutical companies
Trading	Nissei Corporation	
Others	Transportation, Landscaping, Enginee	_⊥ ∌rina. Fertilizer

Forward Looking Statements

The forward looking statements in this material are based on information available at the time of preparation of the material. Although they reflect our current expectations, these statements are not guarantees of future performance, but include a number of risks and uncertainties. Actual results may largely differ from these statements due to various factors which may be beyond company control.

No information in this material is provided as an offer to buy or sell the shares of the company. We urge users of the material to make investment decision based upon own judgment.

